Table 1.

Metabolic markers prior to, during, and after olanzapine treatment

	Case 1a	Case 2	Case 3
Gender	Male	Male	Male
Age (years)	52	58	44
BMI	19.8	18.8	19.6
Height (cm)	154	158	153
Weight (kg)	47	47	46
Medication prior to olanzapine	HAL 12 mg; LP 150 mg;	RIS 4 mg	RIS 4 mg
Olanzapine dose	10 mg	5 mg	15 mg
Loss of consciousness	Yes	No	No
Fasting plasma glucose (mg/dL)
Before olanzapine	86	85	84
On olanzapine	44	57	64
After olanzapine withdrawal and the addition (1 year later) of risperidone 3 mg	87	–	–
Fasting serum insulin (μU/mL)
Before olanzapine	5	5	4
On olanzapine	23	17	40
After olanzapine withdrawal and the addition (1 year later) of risperidone 3 mg	6	–	–
Insulin resistance (HOMA)
Before olanzapine	1.06	1.05	0.83
On olanzapine	2.50	2.39	6.32
After olanzapine withdrawal and the addition (1 year later) of risperidone 3 mg	1.29	–	–
Fasting plasma triglyceride (mg/dL)
Before olanzapine	92	69	90
On olanzapine	88	64	83
After olanzapine withdrawal and the addition (1 year later) of risperidone 3 mg	96	–	–

^acase described in this paper

Abbreviations: BMI, body mass index; HAL, haloperidol; HOMA, homeostasis model assessment; LP, levomepromazine; RIS, risperidone.